Navigation Links
Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
Date:6/3/2008

A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer. Various studies have linked RA to an increased risk of Hodgkin's and non-Hodgkin's lymphoma, leukemia, myeloma, and lung cancer. A link between methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD) commonly prescribed to RA patients, and cancer has also been suggested. Numerous case reports of RA patients treated with MTX developing lymphoma and, even more strikingly, tumors disappearing when the drug was discontinued, have prompted concern that MTX itself may be carcinogenic. So far, however, studies addressing this concern have been inconclusive.

To shed further light on the cancer risk for RA patients treated with MTX, researchers in Australia, where RA affects over 2 percent of adults, studied the cancer incidence in RA patients treated with MTX by local doctors. Their findings, featured in the June 2008 issue of Arthritis Care & Research (www.interscience.wiley.com/journal/arthritis), suggest an increased risk of melanoma, as well as other malignancies, for RA patients receiving MTX.

The study focused on 459 RA patients, 309 women and 150 men, regularly seen by 1 of 6 rheumatologists based in Melbourne. All had started treatment with MTX prior to June 1986. The majority had no previous history of immunosuppressant therapy. 61 percent were rheumatoid factor positive. Researchers set out to determine the cancer incidence in these patients compared with the general population and compared with the results of published studies on the incidence of malignancy in MTX-treated RA populations in other countries. For all patients, followup started on the date they first started MTX therapy and ended on the date of their last confirmed doctor visit or death. Over the total of 4,273 person-years of followup, an average of 9.3 years per patient, 87 malignancies were identified.

Researchers then compared the cancer incidence observed among these RA patients with that of their healthy peers in Victoria, Australia. Standard incidence ratios (SRIs) for all malignancies and for selected cancers were calculated using state population cancer rates, stratified by sex, age (in 5 age groups: under 40, 40-49, 50-59, 60-69, and 70 and over), and calendars years, from 1983-1999. Cox regression analysis was also performed, including positive rheumatoid factor and ever use of two immunosuppressive agents, azathioprine and cyclophosphamide.

RA patients exposed to MTX were found to have an estimated 50 percent excess risk of developing cancer in any form. The risk of non-Hodgkin's lymphoma was more than 5 times higher in RA patients than in the general population. RA patients also had a 3-fold increased risk of melanoma and almost a 3-fold increased risk of lung cancer.

While the increased risk levels for non-Hodgkin's lymphoma and lung cancer were in line with the findings of related studies in Europe and the United States, the high risk for melanoma stood out as novel. "This study is, to our knowledge, the first to report an increased risk of melanoma in patients with RA treated with MTX compared with the general population," notes its lead author, Dr. Rachelle Buchbinder.

Interestingly, the researchers observed a 2.5-fold increased cancer risk for MTX-treated RA patients exposed to cyclophosphamide, but contrary to expectation, no increased risk with exposure to azathioprine.

Despite its limitationslack of a RA control group who was not exposed to MTX, for onethis study has important implications, particularly in regard to the risk of melanoma for RA patients. "Further investigation is needed to determine whether this risk is unique to Australia and what role MTX, immunosuppression per se, and/or environmental factors such as exposure to UV radiation play in its development," Dr. Buchbinder stresses. "Our findings, taken together with other studies investigating the risk of skin cancer in patients with RA, may support a role for regular skin cancer screening for all patients with RA, particularly those receiving immunosuppressive therapy."


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Report confirms increased risk of smoking, substance abuse in bipolar adolescents
2. Fatty liver linked to increased risk of diabetic kidney disease
3. Microsoft HealthVault Be Well Fund Increased to $4.5 Million
4. Unilens Vision Reports Increased Royalty Income
5. Increased screening may better predict those at higher risk for heart disease, researchers report
6. Cumulative radiation exposure shows increased cancer risk for emergency department patients
7. Men at increased risk of death from pneumonia compared to women
8. Somanetics Announces Share Repurchase Program Increased by $15 Million
9. TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity
10. PPO Industry Calls for Increased Collaboration Among Non-Traditional Allies
11. Obese patients face increased risks for infection and dislocation following revision hip surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 20, 2017 , ... AMC Health , the leading provider of proven ... trials market. Similar to its approach in demonstrating positive outcomes in the healthcare market, ... proving the value of eVisits to support virtual studies. , In a ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts ... NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their practice ... can cause for some patients, which is why they offer the latest in modern ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer ... designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle ... twill. , With trendy looks hitting the medical community, UA Flex is for the ...
(Date:6/20/2017)... ... 20, 2017 , ... MEDI+SIGN, a healthcare technology company that ... Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. , “We are eager ... provide invaluable direction for the company,” says Andrew Hoffman, President of MEDI+SIGN. ...
(Date:6/19/2017)... ... June 19, 2017 , ... The joyful summer wedding ... to be a humdinger. A warm winter and wet spring have created ideal conditions ... one wants to be swatting away pesky mosquitoes when a bride and groom are ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... June 8, 2017   Responding to Heath Ledger,s ... the death of singer Chris Cornell in May, ... International offers a free online psychiatric drug ... and families about psychotropic drug risks. The ... died from an accidental overdose, has called for tighter rules ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy & Homecare is ... the United States . The Raizer is a ... fallen person up to an almost-standing position within ... operated by one assistant and does not require ... enough that a child can operate it, and ...
Breaking Medicine Technology: